Cambodia

Population 2017: 16 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>3.1 (2.4–3.5)</td>
<td>19 (13–27)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.41 (0.27–0.57)</td>
<td>2.6 (1.7–3.6)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>52 (36–72)</td>
<td>328 (224–447)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>1.3 (0.89–1.8)</td>
<td>8.2 (5.6–11)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>1.2 (0.52–2.1)</td>
<td>7.2 (3.2–13)</td>
</tr>
</tbody>
</table>

**Estimated TB incidence by age and sex (thousands)*, 2017**

<table>
<thead>
<tr>
<th>0-14 years</th>
<th>&gt; 14 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>3.1 (1.4–4.8)</td>
<td>19 (8.6–29)</td>
</tr>
<tr>
<td>Males</td>
<td>3.4 (1.6–5.3)</td>
<td>27 (12–41)</td>
</tr>
<tr>
<td>Total</td>
<td>6.5 (4–9.1)</td>
<td>46 (28–63)</td>
</tr>
</tbody>
</table>

**TB case notifications, 2017**

Total cases notified: 34,467
Total new and relapse: 34,238
- % with known HIV status: 87%
- % pulmonary: 66%
- % bacteriologically confirmed among pulmonary: 54%

**Universal health coverage and social protection**

TB treatment coverage (notified/estimated incidence), 2017: 66% (48–96)
TB patients facing catastrophic total costs: 0.07 (0.04–0.1)
TB/HIV care in new and relapse TB patients, 2017
Patients with known HIV-status who are HIV-positive: 748 (3%)
- on antiretroviral therapy: 698 (93%)

**Drug-resistant TB care, 2017**

Estimated MDR/RR-TB cases among notified pulmonary TB cases: 560 (290–840)
Estimated % of TB cases with MDR/RR-TB: 1.8% (0.9–3) 11% (3.2–22)
% notified tested for rifampicin resistance: 33% 1313
MDR/RR-TB cases tested for resistance to second-line drugs: 100
Laboratory-confirmed cases
- MDR/RR-TB: 136
- XDR-TB: 1
Patients started on treatment ****
- MDR/RR-TB: 143
- XDR-TB: 1

**Treatment success rate and cohort size**

- New and relapse cases registered in 2016: 94% 32,478
- Previously treated cases, excluding relapse, registered in 2016: 92% 36
- HIV-positive TB cases registered in 2016: 71% 75
- MDR/RR-TB cases started on second-line treatment in 2015: 71% 75
- XDR-TB cases started on second-line treatment in 2015: 0

**TB preventive treatment, 2017**

% of HIV-positive people (newly enrolled in care) on preventive treatment: 21%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 44% (40–48)

**TB financing, 2018**

National TB budget (US$ millions): 37
Funding source: 12% domestic, 24% international, 64% unfunded

---

*Ranges represent uncertainty intervals
**MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
***Includes cases with unknown previous TB treatment history
****Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-04-09

Data: www.who.int/tb/data